IQuity


Decode Health is building an AI and analytics foundation that transforms multiomic and real-world data into precision healthcare. Their modular cloud platform integrates multiomic, clinical, and social drivers of health data to accelerate drug and diagnostic development, providing decision support tools up to 18 times faster than legacy workflows. They partner with pharma, diagnostics, medtech, and health system innovators to de-risk R&D, guide smarter care, and demonstrate economic value.

Industries

health-care
health-diagnostics
medical
service-industry

Nr. of Employees

small (1-50)

IQuity

Nashville, Tennessee, United States, North America


Patents

Long non-coding RNA gene expression signatures in disease monitoring and treatment

US-10982259-B2

View Details

Products

Modular multiomic analytics platform

A cloud-native, modular platform for ingesting, harmonizing, and analyzing multiomic, clinical, and social determinant data to accelerate biomarker discovery, diagnostics development, and CDS creation.

Decode

Decode’s platform moves R&D programs from question to validated findings in weeks, not months. It offers automated multiomics analytics, proprietary patient data, and deep scientific expertise built into a structured program for pharma, diagnostics, and health tech teams to get validated, commercially actionable results on their timeline.


Services

Cloud-hosted, modular analytics platform that ingests, harmonizes, and analyzes multiomic, clinical, and social determinant data; modules can run within the provider's environment or embed into partner ecosystems.

End-to-end biomarker programs combining next-generation sequencing, multiomic fusion, QC pipelines, and analytic validation to identify candidate biomarkers for diagnostics and therapeutics.

Analytics and ML-based services to detect, monitor, and predict outcomes; stratify risk using SDOH and clinical data; and generate actionable insights for targeted testing and interventions.

Rapid assessment service that estimates disease prevalence, affected member counts, per-disease cost, and potential savings for a defined population.

Expertise Areas

  • Biomarker discovery (RNA/DNA/protein)
  • Multiomic data integration
  • Machine learning and AI for diagnostics and risk prediction
  • Population health analytics and clinical decision support
  • Show More (4)

Key Technologies

  • Next-generation sequencing (RNA-seq / NGS)
  • Multiomics data fusion
  • Machine learning / AI models
  • Cloud-native PaaS and elastic compute
  • Show More (4)

News & Updates

Two-year Small Business Innovation Research (SBIR) award strengthens the company’s mission to transform complex biomedical data into real-world solutions; the project will develop a blood-based, AI-driven readout of MS disease biology with Broad Clinical Labs, the Accelerated Cure Project for MS, and a broad network of industry and academic collaborators.

Next-generation RNA sequencing (RNA-seq) enables comprehensive transcriptomic profiling for disease characterization, biomarker discovery, and precision medicine. Despite its potential, RNA-seq has not yet been widely adopted for clinical applications, and a key barrier to its adoption is the variability introduced during processing and analysis. Quality controls (QCs) must be implemented.

Recognition for excellence in healthcare innovation and business performance.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.